Status: Recruiting
An Open-label, Single-arm, Multicenter Phase II Clinical Study of Azacitidine, Chidamide Combined With PD-1 Monoclonal Antibody in the Treatment of Refractory/Relapsed Peripheral T-cell Lymphoma.
An Open-Label, Single-Arm, Multicenter Phase II Clinical Study to Evaluate the Efficacy of Azacitidine, Chidamide, and PD-1 Monoclonal Antibody in the Treatment of Refractory/Relapsed Peripheral T-Cell Lymphoma.
Participants needed: 30
Trial details
Phase: Early Phase 1Age: 18-75Biological sex: AllType: InterventionalSponsor: Second Affiliated Hospital of Soochow UniversityUpdated: May 20, 2026Locations: 1
Eligibility criteria
Age ≥18 years and ≤75 years, male or female. [+12]
History of other malignancies within the past 5 years, except for those treated... [+13]